Vous avez cherché: pomanjkljivostjo (Slovène - Anglais)

bolniki s hudo imunsko pomanjkljivostjo, npr.
patients with severe immunodeficiency states, e.g.

otroci z imunsko pomanjkljivostjo ali sumom nanjo.
infants who have known or suspected immunodeficiency.

podatkov o osebah s pomembno klinično imunsko pomanjkljivostjo ni.
no data are available for individuals with significant clinical immunodeficiency.

m protopya ne smete uporabljati pri bolnikih s prirojeno ali pridobljeno imunsko pomanjkljivostjo in
is protopy should not be used in patients with congenital or acquired immunodeficiencies or in patients

hudo imunsko pomanjkljivostjo, kot je sindrom pridobljene imunske pomanjkljivosti (aids),
severe immunodeficiency states, such as acquired immune deficiency syndrome (aids);

ig ni indiciran pri bolnikih s selektivno pomanjkljivostjo iga, kjer je edini zadržek pomanjkljivost iga.
ivig is not indicated in patients with selective iga deficiency where the iga deficiency is the only abnormality of concern.

pri bolnikih z imunosupresivnim zdravljenjem ali bolnikih z imunsko pomanjkljivostjo lahko zadosten odziv ni dosežen.
in patients receiving immunosuppressive therapy or patients with immunodeficiency, an adequate response may not be achieved.

gastroenteritis z izločanjem cepilnega virusa pri dojenčkih s hudo kombinirano imunsko pomanjkljivostjo (scid)
gastroenteritis with vaccine viral shedding in infants with severe combined immunodeficiency (scid) disorder

bolniki s prirojeno nezmožnostjo ali zmanjšano zmožnostjo tvorbe protiteles (primarno imunsko pomanjkljivostjo),
patients with an inborn inability or reduced ability to produce antibodies (primary immunodeficiencies).

protopya ne smete uporabljati pri bolnikih s prirojeno ali pridobljeno imunsko pomanjkljivostjo in bolnikih, ki prejemajo imunosupresivno terapijo.
protopy should not be used in patients with congenital or acquired immunodeficiencies or in patients on therapy that cause immunosuppression.

imunoglobulin i.v. ni indiciran pri bolnikih s selektivno pomanjkljivostjo iga, pri katerih je edini zadržek pomanjkljivost iga.
ivig is not indicated in patients with selective iga deficiency where the iga deficiency is the only abnormality of concern.

pri bolnikih s kaposijevim sarkomom se po prejemanju zdravila caelyx pojavljajo oportunistične okužbe in so pogoste pri bolnikih z imunsko pomanjkljivostjo zaradi hiv.
opportunistic infections (oi’s) are observed in ks patients after administration with caelyx, and are frequently observed in patients with hiv-induced immunodeficiency.

11,1 % mladih evropejcev zgodaj opušča šolanje in tako vstopijo na trg dela s pomanjkljivostjo, ki jo pozneje težko nadoknadijo23.
11.1% of young europeans leave school early and will enter the labour market with a disadvantage that is very difficult to overcome later23.

bolniki z redkimi dednimi težavami intolerance galaktoze, pomanjkljivostjo laktaze lapp ali malabsorpcije glukoze-galaktoze ne smejo jemati tega zdravila.
patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicine.

vendar pa je cepljenje oseb s kronično imunsko pomanjkljivostjo (npr. okužbo s hiv) priporočljivo navkljub morebitnemu omejenemu protitelesnemu odzivu.
nevertheless, vaccination of subjects with chronic immunodeficiency such as hiv infection is recommended even if the antibody response might be limited.

pri bolnikih, ki se zdravijo z zdravili za zaviranje imunske odzivnosti, ali bolnikih z imunsko pomanjkljivostjo se lahko pričakuje, da ne bo dosežen zadosten imunski odziv.
it may be expected that in patients receiving immunosuppressive treatment or patients with immunodeficiency, an adequate response may not be achieved.

pri s hiv okuženih bolnikih s hudo imunsko pomanjkljivostjo lahko ob uvedbi kombiniranega protiretrovirusnega zdravljenja (cart) nastane vnetna reakcija na asimptomatične ali rezidualne oportunistične okužbe.
in hiv-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (cart), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise.

prvo kot nadomestno zdravljenje pri bolnikih s primarno imunsko pomanjkljivostjo (tako pri odraslih kot tudi pri otrocih starih nad 10 let) in drugo kot imunomodulacijo pri odraslih bolnikih z imunsko trombocitopenično purpuro.
two clinical trials were performed with flebogammadif, one for replacement therapy in patients with primary immunodeficiency (both in adults and in children above 10 years) and another for immunomodulation in adults patients with immune thrombocytopenic purpura.

pri bolnikih s primarno imunsko pomanjkljivostjo (pid - "primary immunodeficiency") iz evrope in zda so opravili dve klinični preskušanji z zdravilom kiovig.
two clinical trials with kiovig were performed in primary immunodeficiency (pid) patients in europe and the us.

ker to zdravilo vsebuje saharozo, bolniki z redko dedno intoleranco za fruktozo, malabsorpcijo glukoze/galaktoze ali pomanjkljivostjo saharaze-izomaltaze, tega zdravila ne smejo jemati.
as this medicinal product contains sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.